I'm curious, maybe we'll see a new partnership with $LLY (-0,22 %) the long term, but this could also take time, due to the warning, so to speak, that the $HIMS (-0,62 %) sales strategy has negative effects on patients... The change of CEO could also lead in a different direction, so that they try it alone:
